TG Therapeutics TGTX Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 83.7%-4.6pp | 88.3%-5.6pp | 94%— | —— | |
| Operating margin | 20%+7.3pp | 12.7%— | —— | -7,841.8%-2,688pp | |
| Net margin | 72.6%+65.5pp | 7.1%— | —— | -8,039.2%-2,835pp | |
| Returns | |||||
| Return on equity | 102.8%+90.5pp | 12.2%— | —— | -151.4%-59.3pp | |
| Return on invested capital | 22%+5.9pp | 16.1%— | —— | -770.7%+1,966pp | |
| Efficiency | |||||
| Asset turnover | 0.8×0.0× | 0.7×-0.2× | 0.9×+0.9× | 0×0.0× | |
| Liquidity | |||||
| Current ratio | 4.1×-2.1× | 6.2×+0.3× | 5.9×+2.8× | 3.2×-1.9× | |
| Leverage | |||||
| Debt-to-equity | 0.4×-0.7× | 1.1×+0.5× | 0.7×-0.7× | 1.4×+1.1× | |
| Net debt / EBITDA | 1.4×-0.3× | 1.8×— | —— | —— | |
| Per Share | |||||
| Book value per share | $4.01+189% | $1.39+28.3% | $1.08+150% | $0.43-75.9% | |
| Valuation | |||||
| Market capitalization | $4.73B+1.0% | $4.69B+81.2% | $2.59B+50.4% | $1.72B-36.7% | |
| Price / earnings | 10.6×-190× | 200.4×— | —— | —— | |
| Price / sales | 7.7×-6.6× | 14.2×+3.2× | 11.1×-607× | 617.6×+212× | |
| Price / book | 7.3×-13.8× | 21.1×+5.0× | 16.1×-13.2× | 29.3×+17.9× | |
| EV / EBITDA | 39.8×-73.6× | 113.3×— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are TG Therapeutics's profit margins?
- TG Therapeutics (TGTX) runs a 83.1% gross margin and a 21.3% operating margin, with a 66.0% net margin.
- Where do TG Therapeutics's ratios come from?
- Every ratio is computed from TG Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
